RELATED STUDY
Key Findings:
Type of Study:
Study Result: Inconclusive
Research Location(s):
Year of Pub:
Cannabinoids Studied:
Chemotype:
Terpenes Studied:
Receptors Studied:
Ligands Studied:
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration:
Dosing Regimen: BCP (25 or 50 mg/kg)
Clinical Relevance: BCP preventively or therapeutically blocked the development and progression of clinical and neurological signs of EAE, which was correlated with the hindrance of immune cell activation, neuroinflammation, and demyelinating processes in the CNS.
Citation:
